

Antonio Fernandez-Nebro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3814346/publications.pdf>

Version: 2024-02-01

137
papers

7,806
citations

109321

35
h-index

53230

85
g-index

148
all docs

148
docs citations

148
times ranked

7119
citing authors

#	ARTICLE	IF	CITATIONS
1	Hospitalizaciones y mortalidad por COVID-19 en pacientes con enfermedades inflamatorias reumáticas en Andalucía. <i>Reumatología Clínica</i> , 2022, 18, 422-428.	0.5	2
2	Hospitalization and mortality from COVID-19 of patients with rheumatic inflammatory diseases in Andalusia. <i>Reumatología Clínica (English Edition)</i> , 2022, 18, 422-428.	0.3	4
3	Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 2596-2602.	1.9	4
4	Postprandial Hyperlipidemia: Association with Inflammation and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis. <i>Biomedicines</i> , 2022, 10, 133.	3.2	6
5	Efficacy and Safety of Rituximab in Autoimmune Disease-Associated Interstitial Lung Disease: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 927.	2.4	5
6	Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study. <i>Rheumatology</i> , 2022, 62, 217-224.	1.9	1
7	Importance of Vaccination against SARS-CoV-2 in Patients with Interstitial Lung Disease Associated with Systemic Autoimmune Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 2437.	2.4	5
8	Systematic Review and Metaanalysis of Worldwide Incidence and Prevalence of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis. <i>Journal of Clinical Medicine</i> , 2022, 11, 2573.	2.4	26
9	Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis. <i>EBioMedicine</i> , 2022, 80, 104053.	6.1	9
10	Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease. <i>Biomedicines</i> , 2022, 10, 1480.	3.2	9
11	Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 133-142.	2.2	27
12	Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 245-249.	0.3	0
13	Psychological factors associated with sleep disorders in patients with axial spondyloarthritis or psoriatic arthritis: A multicenter cross-sectional observational study. <i>Journal of Clinical Nursing</i> , 2021, 30, 266-275.	3.0	12
14	Incidence and case fatality rate of COVID-19 in patients with inflammatory articular diseases. <i>International Journal of Clinical Practice</i> , 2021, 75, e13707.	1.7	13
15	Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER). <i>Rheumatology</i> , 2021, 60, 1793-1803.	1.9	23
16	Evaluation of cognitive function in adult patients with juvenile idiopathic arthritis. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 81-89.	1.9	1
17	Cumulative inflammatory burden and obesity as determinants of insulin resistance in patients with established rheumatoid arthritis: cross-sectional study. <i>BMJ Open</i> , 2021, 11, e044749.	1.9	9
18	Meningoencefalitis por <i>Cryptococcus neoformans</i> y virus varicela-zoster en paciente con lupus eritematoso sistémico. <i>Neurología</i> , 2021, 36, 719-719.	0.7	1

#	ARTICLE	IF	CITATIONS
19	Predictors of Progression and Mortality in Patients with Prevalent Rheumatoid Arthritis and Interstitial Lung Disease: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 874.	2.4	30
20	Effectiveness, safety and economic analysis of Benepali in clinical practice. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 588-594.	0.3	2
21	Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 1368-1382.	2.9	5
22	Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?. <i>Rheumatology</i> , 2021, 60, 5329-5336.	1.9	4
23	Aportaciones del registro de lupus de la Sociedad Española de Reumatología (RELESSER) al conocimiento del lupus eritematoso sistémico en España. <i>Reumatología Clínica</i> , 2021, 17, 245-249.	0.5	0
24	Meningoencephalitis caused by <i>Cryptococcus neoformans</i> and varicella-zoster virus in a patient with systemic lupus erythematosus. <i>Neurología (English Edition)</i> , 2021, 36, 719-721.	0.4	0
25	Adiposity Is Related to Inflammatory Disease Activity in Juvenile Idiopathic Arthritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3949.	2.4	7
26	Human motion capture for movement limitation analysis using an RGB-D camera in spondyloarthritis: a validation study. <i>Medical and Biological Engineering and Computing</i> , 2021, 59, 2127-2137.	2.8	0
27	Characteristics and Predictors of Progression Interstitial Lung Disease in Rheumatoid Arthritis Compared with Other Autoimmune Disease: A Retrospective Cohort Study. <i>Diagnostics</i> , 2021, 11, 1794.	2.6	10
28	Ability to Participate in Social Activities of Rheumatoid Arthritis Patients Compared with Other Rheumatic Diseases: A Cross-Sectional Observational Study. <i>Diagnostics</i> , 2021, 11, 2258.	2.6	8
29	Relationship between polyautoimmunity and sarcopenic obesity in rheumatoid arthritis patients. <i>Reumatología Clínica (English Edition)</i> , 2021, , .	0.3	1
30	Bacteremia in Systemic Lupus Erythematosus in Patients from a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes. <i>Journal of Rheumatology</i> , 2020, 47, 234-240.	2.0	19
31	Hormonal Dependence and Cancer in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 216-224.	3.4	11
32	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. <i>Rheumatology</i> , 2020, 59, 2043-2051.	1.9	10
33	Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the Tj ETQq1 10.784314rgBT /Ove		
34	Postprandial Apolipoprotein B48 is Associated with Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2483.	2.4	11
35	Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1544-1549.	0.9	173
36	Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. <i>Lupus</i> , 2020, 29, 1556-1565.	1.6	19

#	ARTICLE	IF	CITATIONS
37	Expansion of Rare and Harmful Lineages is Associated with Established Rheumatoid Arthritis. Journal of Clinical Medicine, 2020, 9, 1044.	2.4	26
38	SAT0006â€¦SIMULTANEOUS ANALYSIS OF ANTI-CCP, RHEUMATOID FACTOR, ANTI-PAD4 AND ANTI-CARBAMYLATED PROTEIN ANTIBODIES REVEALS INTERACTION EFFECTS WITH RESPONSE TO ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 933.2-934.	0.9	0
39	Patrones de tratamiento biolÃ³gico en pacientes con enfermedades articulares inflamatorias. Estudio retrospectivo de 4 aÃ±os de seguimiento. ReumatologÃa ClÃnica, 2020, 16, 447-454.	0.5	1
40	A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis. Frontiers in Immunology, 2019, 10, 1459.	4.8	24
41	Prevalence of Comorbidities in Rheumatoid Arthritis and Evaluation of Their Monitoring in Clinical Practice: The Spanish Cohort of the COMORA Study. ReumatologÃa ClÃnica (English Edition), 2019, 15, 102-108.	0.3	3
42	SAT0199â€¦POLYAUTOIMMUNITY IN SYSTEMIC LUPUS ERYTHEMATOSUS. DATA FROM A LARGE SPANISH COHORT: SPANISH SOCIETY OF RHEUMATOLOGY REGISTRY OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (RELESSER).. , 2019, , .		0
43	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study. ReumatologÃa ClÃnica, 2019, 15, 102-108.	0.5	27
44	AnÃ¡lisis de la efectividad, seguridad y optimizaciÃ³n de tocilizumab en una cohorte de pacientes con artritis reumatoide en prÃ¡ctica clÃnica. ReumatologÃa ClÃnica, 2019, 15, 21-26.	0.5	7
45	Eficacia y seguridad de rituximab en neuropatÃa vasculÃtica: revisiÃ³n sistemÃtica. ReumatologÃa ClÃnica, 2019, 15, 173-178.	0.5	4
46	FRI0739-HPRâ€¦Expert recommendations on psychological needs of patients with rheumatoid arthritis. , 2018, , .		0
47	Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort. Arthritis Research and Therapy, 2018, 20, 280.	3.5	40
48	Expert recommendations on the psychological needs of patients with rheumatoid arthritis. Rheumatology International, 2018, 38, 2167-2182.	3.0	12
49	Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2017, 47, 38-45.	3.4	117
50	Management of cardiovascular risk in systemic lupus erythematosus: a systematic review. Lupus, 2017, 26, 1407-1419.	1.6	15
51	Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study. Rheumatology International, 2017, 37, 1709-1718.	3.0	18
52	Genome-wide pathway analysis identifies VEGF pathway association with oral ulceration in systemic lupus erythematosus. Arthritis Research and Therapy, 2017, 19, 138.	3.5	14
53	Comorbidities in Patients With Primary SjÃ¶gren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registriesâ€Based Study. Arthritis Care and Research, 2017, 69, 38-45.	3.4	27
54	Genetic variation associated with cardiovascular risk in autoimmune diseases. PLoS ONE, 2017, 12, e0185889.	2.5	5

#	ARTICLE	IF	CITATIONS
55	Eficiencia de diferentes dosis de rituximab en la artritis reumatoide. <i>Reumatología Clínica</i> , 2016, 12, 139-145.	0.5	5
56	A genome-wide association study identifies <i>SLC8A3</i> as a susceptibility locus for ACPA-positive rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 1106-1111.	1.9	14
57	Urine metabolome profiling of immune-mediated inflammatory diseases. <i>BMC Medicine</i> , 2016, 14, 133.	5.5	97
58	A functional variant of TLR10 modifies the activity of NFκB and may help predict a worse prognosis in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 221.	3.5	35
59	Quality Standards for Rheumatology Outpatient Clinic. The EXTRELLA Project. <i>Reumatología Clínica (English Edition)</i> , 2016, 12, 248-255.	0.3	2
60	Identification of <i>IRX1</i> as a Risk Locus for Rheumatoid Factor Positivity in Rheumatoid Arthritis in a Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 1384-1391.	5.6	6
61	Insulin resistance and levels of adipokines in patients with untreated early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 43-53.	2.2	29
62	Estándares de calidad asistencial para las consultas externas de reumatología. El proyecto EXTRELLA. <i>Reumatología Clínica</i> , 2016, 12, 248-255.	0.5	10
63	Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2016, 16, 137-140.	2.0	31
64	A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2016, 16, 147-150.	2.0	30
65	Cardiovascular Events in Systemic Lupus Erythematosus. <i>Medicine (United States)</i> , 2015, 94, e1183.	1.0	96
66	FRI0424...Cardiovascular Events in Systemic Lupus Erythematosus (Sle): A Nationwide Study in Spain (Relesser Registry). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 580.2-581.	0.9	0
67	Rheumatoid arthritis response to treatment across IgG1 allotype "anti-TNF incompatibility: a case-only study. <i>Arthritis Research and Therapy</i> , 2015, 17, 63.	3.5	9
68	Variation at FCGR2A and Functionally Related Genes Is Associated with the Response to Anti-TNF Therapy in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015, 10, e0122088.	2.5	33
69	Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 720-729.	1.6	20
70	Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. <i>Rheumatology</i> , 2015, 54, 2042-2050.	1.9	61
71	Eficacia y seguridad de golimumab añadido a fármacos antirreumáticos modificadores de la enfermedad en artritis reumatoide. Resultados del estudio GO-MORE en España. <i>Reumatología Clínica</i> , 2015, 11, 144-150.	0.5	3
72	<i>FCGR</i> polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. <i>Pharmacogenomics</i> , 2015, 16, 333-345.	1.3	21

#	ARTICLE	IF	CITATIONS
73	Comprehensive Description of Clinical Characteristics of a Large Systemic Lupus Erythematosus Cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) With Emphasis on Complete Versus Incomplete Lupus Differences. <i>Medicine (United States)</i> , 2015, 94, e267.	1.0	48
74	Actualizaci3n 2014 del Documento de Consenso de la Sociedad Espa3ola de Reumatolog3a sobre el uso de terapias biol3gicas en la artritis reumatoide. <i>Reumatolog3a Cl3nica</i> , 2015, 11, 279-294.	0.5	89
75	Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1011-1018.	0.9	610
76	Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. <i>Arthritis Research and Therapy</i> , 2014, 16, R66.	3.5	25
77	Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 238-245.	1.5	32
78	Tocilizumab en pacientes con artritis reumatoide activa y respuesta inadecuada a fármacos antirreumáticos modificadores de la enfermedad o antagonistas del factor de necrosis tumoral: subanálisis de los datos espa3oles de un estudio abierto cercano a la pr3ctica cl3nica habitual. <i>Reumatolog3a Cl3nica</i> , 2014, 10, 94-100.	0.5	5
79	Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 175-185.	3.4	101
80	A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. <i>Arthritis Research and Therapy</i> , 2014, 16, R6.	3.5	37
81	The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB). <i>Lupus</i> , 2014, 23, 1014-1022.	1.6	9
82	Reducing the Need for Central Dual-Energy X-Ray Absorptiometry in Postmenopausal Women: Efficacy of a Clinical Algorithm Including Peripheral Densitometry. <i>Calcified Tissue International</i> , 2013, 93, 62-68.	3.1	3
83	Quality-of-care standards for early arthritis clinics. <i>Rheumatology International</i> , 2013, 33, 2459-2472.	3.0	6
84	Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: A case control study. <i>Reumatolog3a Cl3nica</i> , 2013, 9, 18-23.	0.5	17
85	Consenso de la Sociedad Espa3ola de Reumatolog3a sobre el uso de terapias biol3gicas en el lupus eritematoso sist3mico. <i>Reumatolog3a Cl3nica</i> , 2013, 9, 281-296.	0.5	31
86	Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: A case control study. <i>Reumatolog3a Cl3nica (English Edition)</i> , 2013, 9, 18-23.	0.3	0
87	SER Consensus Statement on the Use of Biologic Therapy for Systemic Lupus Erythematosus. <i>Reumatolog3a Cl3nica (English Edition)</i> , 2013, 9, 281-296.	0.3	10
88	Incidence of Cancer in a Cohort of Spanish Patients With Systemic Lupus Erythematosus. <i>Reumatolog3a Cl3nica</i> , 2013, 9, 359-364.	0.5	12
89	Incidence of Cancer in a Cohort of Spanish Patients With Systemic Lupus Erythematosus. <i>Reumatolog3a Cl3nica (English Edition)</i> , 2013, 9, 359-364.	0.3	0
90	GWAS replication study confirms the association of <i>SLCO1C1</i> with anti-TNF therapy response in rheumatoid arthritis. <i>Pharmacogenomics</i> , 2013, 14, 727-734.	1.3	61

#	ARTICLE	IF	CITATIONS
91	Implication of <i>IL-2/IL-21</i> region in systemic sclerosis genetic susceptibility. Annals of the Rheumatic Diseases, 2013, 72, 1233-1238.	0.9	30
92	Systemic Lupus Erythematosus: Genomics, Mechanisms, and Therapies. Clinical and Developmental Immunology, 2012, 2012, 1-2.	3.3	12
93	A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Human Molecular Genetics, 2012, 21, 926-933.	2.9	74
94	Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes. Human Molecular Genetics, 2012, 21, 4549-4557.	2.9	79
95	The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis. Genes and Immunity, 2012, 13, 191-196.	4.1	23
96	Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus, 2012, 21, 1063-1076.	1.6	98
97	Evaluation of a Shared Autoimmune Disease-associated Polymorphism of TRAF6 in Systemic Sclerosis and Giant Cell Arteritis. Journal of Rheumatology, 2012, 39, 1275-1279.	2.0	3
98	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Human Molecular Genetics, 2012, 21, 2825-2835.	2.9	98
99	Influence of the <i>IL6</i> Gene in Susceptibility to Systemic Sclerosis. Journal of Rheumatology, 2012, 39, 2294-2302.	2.0	34
100	Clinicopathologic correlations of renal microthrombosis and inflammatory markers in proliferative lupus nephritis. Arthritis Research and Therapy, 2012, 14, R126.	3.5	22
101	Survival of Lupus Nephritis Patients After Renal Transplantation In Malaga. Transplantation Proceedings, 2012, 44, 2067-2068.	0.6	8
102	Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. Arthritis Research and Therapy, 2012, 14, R154.	3.5	11
103	A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. Arthritis Research and Therapy, 2012, 14, R85.	3.5	32
104	No evidence of association between functional polymorphisms located within <sc><i>IL6R</i></sc> and <sc><i>IL6ST</i></sc> genes and systemic sclerosis. Tissue Antigens, 2012, 80, 254-258.	1.0	4
105	Effectiveness of a clinical practice intervention in early rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 321-330.	3.4	17
106	A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. Arthritis and Rheumatism, 2012, 64, 264-271.	6.7	77
107	A replication study confirms the association of <i>TNFSF4 (OX40L)</i> polymorphisms with systemic sclerosis in a large European cohort. Annals of the Rheumatic Diseases, 2011, 70, 638-641.	0.9	63
108	Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 454-462.	0.9	75

#	ARTICLE	IF	CITATIONS
109	Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population. <i>Rheumatology</i> , 2011, 50, 1976-1981.	1.9	27
110	BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 700-705.	0.9	96
111	Long-term TNF- α Blockade in Patients with Amyloid A Amyloidosis Complicating Rheumatic Diseases. <i>American Journal of Medicine</i> , 2010, 123, 454-461.	1.5	49
112	Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1428-1432.	0.9	262
113	Amyloidosis. <i>Medicine</i> , 2009, 10, 2185-2191.	0.0	0
114	The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. <i>Rheumatology</i> , 2008, 47, 1088-1092.	1.9	100
115	Anti-Cofactor Autoantibodies in Systemic Lupus Erythematosus: Prevalence, Clinical and HLA Class II Associations. <i>Immunological Investigations</i> , 2008, 37, 375-385.	2.0	13
116	The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. <i>Rheumatology</i> , 2008, 47, 1732-1733.	1.9	24
117	Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naïve rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 2334-42.	2.0	31
118	Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the "Euro-Lupus Project". <i>Autoimmunity Reviews</i> , 2006, 5, 180-186.	5.8	115
119	Anti-TNF-alpha for treatment of amyloidosis associated with Crohn's disease. <i>Gut</i> , 2006, 55, 1666-7; author reply 1667.	12.1	7
120	Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. <i>American Journal of Medicine</i> , 2005, 118, 552-556.	1.5	92
121	Systemic lupus erythematosus in southern Spain: a comparative clinical and genetic study between Caucasian and Gypsy patients. <i>Lupus</i> , 2004, 13, 934-940.	1.6	18
122	HLA-DPB1 alleles association of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. <i>Lupus</i> , 2003, 12, 560-563.	1.6	52
123	Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period. <i>Medicine (United States)</i> , 2002, 81, 169-178.	1.0	39
124	HLA Class II DNA Typing in a Large Series of European Patients with Systemic Lupus Erythematosus. <i>Medicine (United States)</i> , 2002, 81, 169-178.	1.0	39
125	Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. <i>Arthritis and Rheumatism</i> , 2002, 46, 1019-1027.	6.7	1,736
126	HLA class II alleles associations of anticardiolipin and anti b2GPI antibodies in a large series of European patients with systemic lupus erythematosus. <i>Lupus</i> , 2000, 9, 47-55.	1.6	80

#	ARTICLE	IF	CITATIONS
127	Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological, and HLA class II gene associations. European Concerted Action on the Immunogenetics of SLE. <i>Journal of Rheumatology</i> , 2000, 27, 135-41.	2.0	45
128	Anticardiolipin and anti-Î²2GPI antibodies in a large series of European patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 1999, 28, 344-351.	1.1	57
129	Anticardiolipin and anti-Î²2GPI antibodies in a large series of European patients with systemic lupus erythematosus: Prevalence and clinical associations. <i>Scandinavian Journal of Rheumatology</i> , 1999, 28, 344-351.	1.1	29
130	Chronic or recurrent headache in patients with systemic lupus erythematosus: a case control study. <i>Lupus</i> , 1999, 8, 151-157.	1.6	45
131	Morbidity and Mortality in Systemic Lupus Erythematosus During a 5-Year Period: A Multicenter Prospective Study of 1,000 Patients. <i>Medicine (United States)</i> , 1999, 78, 167-175.	1.0	367
132	Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. <i>Scandinavian Journal of Rheumatology</i> , 1999, 28, 344-51.	1.1	38
133	Central vein thrombosis in the antiphospholipid syndrome. <i>Lupus</i> , 1997, 6, 549-551.	1.6	6
134	Palmar fasciitis and polyarthritis syndrome is multicausal. <i>Clinical Rheumatology</i> , 1996, 15, 99-101.	2.2	6
135	Localized rheumatoid vasculitis presenting as acute alithiasic cholecystitis. <i>American Journal of Medicine</i> , 1991, 91, 90-92.	1.5	16
136	Psoas abscess secondary to brucellosis. <i>Journal of Infection</i> , 1991, 22, 107-109.	3.3	13
137	Osteoarticular complications of brucellosis.. <i>Annals of the Rheumatic Diseases</i> , 1991, 50, 23-26.	0.9	111